Equities Analysts Issue Forecasts for Biora Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:BIOR)

Biora Therapeutics, Inc. (NASDAQ:BIOR) – HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Biora Therapeutics in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst J. Pantginis expects that the company will earn ($0.45) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Biora Therapeutics’ current full-year earnings is ($2.06) per share. HC Wainwright also issued estimates for Biora Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.52) EPS and Q4 2024 earnings at ($0.49) EPS.

Biora Therapeutics Stock Performance

NASDAQ BIOR opened at $0.70 on Wednesday. The stock has a market capitalization of $21.19 million, a price-to-earnings ratio of -0.08 and a beta of 1.09. Biora Therapeutics has a twelve month low of $0.67 and a twelve month high of $6.70. The stock has a 50-day moving average of $1.01 and a 200 day moving average of $1.34.

Hedge Funds Weigh In On Biora Therapeutics

Hedge funds have recently made changes to their positions in the company. Armistice Capital LLC purchased a new stake in shares of Biora Therapeutics in the fourth quarter valued at approximately $1,102,000. Neuberger Berman Group LLC purchased a new stake in shares of Biora Therapeutics in the third quarter valued at approximately $3,172,000. Vanguard Group Inc. purchased a new stake in shares of Biora Therapeutics in the third quarter valued at approximately $2,860,000. Millennium Management LLC grew its position in shares of Biora Therapeutics by 99.3% in the fourth quarter. Millennium Management LLC now owns 1,854,620 shares of the company’s stock valued at $244,000 after purchasing an additional 924,199 shares in the last quarter. Finally, BlackRock Inc. purchased a new stake in shares of Biora Therapeutics in the third quarter valued at approximately $789,000. Institutional investors and hedge funds own 43.74% of the company’s stock.

About Biora Therapeutics

Biora Therapeutics, Inc, a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and Systemic oral delivery platform for oral delivery of large molecules for management of chronic diseases.